Zymeworks BC EBIT

Zymeworks BC (ZYME) currently reports a EBIT of $-110B as of June 2026. That compares with $-34B in the prior-year period — down 225.4% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Zymeworks BC's EBIT history and peer comparisons.

Zymeworks BC's EBIT decreased from $-34B to $-110B — a 225.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zymeworks BC's EBIT of $-110B is lower than the Healthcare sector average of $110B. That is roughly 203.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Zymeworks BC reported $-110B in EBIT as of June 2026. That compares with $-34B in the prior-year period — down 225.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-110B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Zymeworks BC, and consider following ZYME for alerts when major investors trade the stock.